Deepu Madduri, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Madduri’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A107001 · Current
Licensed to practise in California · since 2009 · expires 2026-12-31 · University of Oklahoma College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$47 in 2025
| 2025 | 1 | 1 | None | $47 |
| 2024 | 2 | 3 | None | $1,981 |
| 2023 | 2 | 3 | None | $163 |
| 2022 | 1 | 1 | None | $103 |
| 2021 | 6 | 10 | $33,024 | $33,024 |
| 2020 | 10 | 50 | $121,780 | $126,258 |
| 2019 | 8 | 96 | $176,120 | $186,366 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Global Services | Darzalex | $47 | 1 payment
|
See the published payment
| Janssen Global Services | Meals · 2025-09-17 | Darzalex | $47 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,981
| E.R. Squibb & Sons L.L.C. | None | $1,955 | 2 payments
|
| Legend Biotech USA | None | $26 | 1 payment
|
2023: $163
| Genzyme | None | $84 | 1 payment
|
| Legend Biotech USA | None | $79 | 2 payments
|
2022: $103
| Genzyme | None | $103 | 1 payment
|
2021: $33,024
| Foundation Medicine | Foundationone Cdx | $24,449 | 1 payment
|
| Janssen Biotech | None | $2,525 | 2 payments
|
| Celgene | None | $2,063 | 1 payment
|
| GlaxoSmithKline | Blenrep | $1,950 | 1 payment
|
| Janssen Research & Development | None | $1,240 | 1 payment
|
| Janssen Global Services | None | $797 | 4 payments
|
2020: $126,258
| Foundation Medicine | Foundationone Liquid | $78,335 | 10 payments
|
| Janssen Global Services | Imbruvica | $15,990 | 14 payments
|
| GlaxoSmithKline | Blenrep | $9,100 | 6 payments
|
| Celgene | Revlimid | $5,290 | 4 payments
|
| Janssen Scientific Affairs | None | $5,270 | 1 payment
|
| Genzyme | Sarclisa | $4,782 | 3 payments
|
| Janssen Biotech | Darzalex | $4,658 | 5 payments
|
| Janssen Research & Development | Edurant | $2,114 | 5 payments
|
| Ethicon Endo-Surgery | None | $594 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $125 | 1 payment
|
2019: $186,366
| Foundation Medicine | Foundationact | $112,125 | 17 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $30,754 | 23 payments
|
| Celgene | Bb-2121 | $19,499 | 22 payments
|
| Janssen Global Services | Pipeline | $14,012 | 12 payments
|
| Janssen Biotech | Darzalex | $9,443 | 17 payments
|
| E.R. Squibb & Sons L.L.C. | None | $307 | 3 payments
|
| Amgen | None | $125 | 1 payment
|
| Secura Bio | Farydak | $102 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · Ph Iib Ide-Cel Multi-Cohort Mono Rrmm · 2020 | Their institution | $880,575 |
| Celgene Corporation · Ph Iib Ide-Cel Multi-Cohort Mono Rrmm (Bb2121-Mm-002) · 2019 | Their institution | $394,527 |
| Celgene Corporation · Ph Iib Ide-Cel Multi-Cohort Mono Rrmm - A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Evaluate the Efficacy and Safety of Bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma · 2022 | Their institution | $389,260 |
| Amgen Inc. · Amg 701 Ph1/2 Non-Randomized Open-Label Expansion Mm · 2020 | Their institution | $367,548 |
| Amgen Inc. · Amg 701 Non-Randomized Open-Label Expansion Multiple Myeloma 20170122 · 2019 | Their institution | $249,318 |
| Janssen Research & Development, LLC · A Phase 2 Multicohort Open Label Study of Jnj68284528 A Chimeric Antigen Receptor T Cell Cart Therapy Directed Against Bcma in Subjects With Multiple Myeloma · 2021 | Their institution | $202,343 |
| Janssen Research & Development, LLC · A Phase 2, Multicohort Open-Label Study of Jnj-68284528, A Chimeric Antigen Receptor T Cell (Car-T) Therapy Directed Against Bcma in Subjects With Multiple Myeloma · 2020 | Their institution | $195,204 |
| Celgene Corporation · (Cc-99712-Mm-001) Ph I R/R Mm - A Phase 1, Multicenter, Open-Label, Dose Finding Study of Cc-99712, A Bcma Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma · 2023 | Their institution | $185,906 |
| Celgene Corporation · (Cc-99712-Mm-001) Ph I R/R Mm Dose Escalation (Bms Study Number: Ca060-P01) · 2020 | Their institution | $128,904 |
| Celgene Corporation · A Phase 1, Multicenter, Open-Label, Dose Finding S · 2021 | Their institution | $111,687 |
| Celgene Corporation · A Phase 2, Multi-Cohort, Open-Label, Multicenter S · 2021 | Their institution | $87,997 |
| Celgene Corporation · A Phase I, Multi Center, Open Label Study of Cc-98633, Bcma Targeted Nex-T Chimeric Antigen Receptor (Car) T Cells, in Subjects With Relapsed and/Or Refractory Multiple Myeloma · 2020 | Their institution | $65,988 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Fih Study of Regn5459 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma · 2020 | Their institution | $32,764 |
| Amgen Inc. · Amg 701 P1/2 Non-Randomized Open-Label Expansion Mm · 2021 | Their institution | $2,899 |
| Celgene Corporation · Crb-401 A Phase 1 Study of Bb2121 in Bcma-Expressing Multiple Myeloma (Crb-401) · 2019 | This clinician | $2,866 |
| Amgen Inc. · Amg 701 P1/2 Non-Randomized Open-Label Expansion Mm · 2023 | Their institution | $2,087 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma · 2020 | This clinician | $1,022 |
| Regeneron Pharmaceuticals, Inc. · Phase 1 2 Fih Study of Regn5458 Anti-Bcma X Anti-Cd3 Bispecific Antibody in Patients With Relapsed Or Refractory Multiple Myeloma · 2019 | This clinician | $802 |
| Regeneron Pharmaceuticals, Inc. · Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma · 2021 | This clinician | $708 |
Professional record
- NPI
- 1740418318
- Licence
- CA A107001, NY 282643California A107001: Current · expires 2026-12-31
- Trained
- University of Oklahoma College of Medicine, 2007
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-06-23
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.